News & events

News & events

10.09.2024
Management TeamNews

VarmX announces appointment of Martijn Negen as COO

Read more

25.05.2023
News

VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it...

Read more

18.09.2017
News

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

VarmX announces publication in Nature Communications of groundbreaking snake venom inspired approach to restore blood clotting in patients using...

Read more

13.09.2017
Scientific publications

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

Read more

27.06.2017
News

VarmX raises seed capital for development of VMX-C001

VarmX, a Dutch, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and...

Read more

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs